.
CLDX financial statements
* Numbers in thousands
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
Capitalization * |
177 360 | 420 153 | 2 106 921 | 1 914 936 | 805 527 | 329 971 | 359 922 | 64 218 | 33 511 | 313 641 | 452 038 |
EV * |
180 824 | 406 594 | 1 937 519 | 1 889 508 | 737 837 | 287 510 | 326 200 | 44 434 | 24 223 | 271 132 | 271 132 |
Stock price $ |
67.35 | 109.2 | 396.15 | 321.3 | 124.5 | 48.75 | 42 | 6.15 | 2.31 | 21.62 | 31.16 |
Number of shares * |
2 633 | 3 848 | 5 318 | 5 960 | 6 470 | 6 769 | 8 570 | 10 442 | 14 507 | 14 507 | 14 507 |
EPS |
-17,01 | -15,37 | -15,33 | -19,81 | -19,66 | -18,99 | -10,86 | -14,48 | -3,51 | -4,12 | -4,12 |
Revenue * |
9 265 | 11 202 | 4 111 | 3 586 | 5 480 | 6 786 | 12 743 | 9 538 | 3 573 | 7 418 | 7 418 |
Net income * |
-44 799 | -59 123 | -81 550 | -118 080 | -127 197 | -128 530 | -93 031 | -151 184 | -50 878 | -59 780 | -59 780 |
Operating profit * |
-43 449 | -58 077 | -81 442 | -122 430 | -129 541 | -132 916 | -109 327 | -76 404 | -54 525 | -49 572 | -49 572 |
Total liabilities * |
29 272 | 29 767 | 27 300 | 36 354 | 47 479 | 117 927 | 79 255 | 31 749 | 28 907 | 26 481 | 26 481 |
Net debt * |
3 464 | -13 559 | -169 402 | -25 428 | -67 690 | -42 461 | -33 722 | -19 784 | -7 575 | -40 355 | -40 355 |
Total assets * |
97 994 | 125 541 | 347 095 | 248 014 | 337 584 | 383 358 | 315 624 | 155 809 | 122 933 | 235 838 | 235 838 |
Equity * |
68 722 | 95 774 | 319 795 | 211 660 | 290 105 | 265 431 | 236 369 | 124 060 | 94 026 | 209 357 | 209 357 |
Cash and investments * |
53 312 | 83 962 | 302 983 | 201 043 | 289 889 | 189 776 | 139 427 | 94 022 | 64 383 | 194 422 | 194 422 |
Over the past 10 years, the maximum capitalization of Celldex Therapeutics, Inc. is 2 106 921, the minimum is 33 511. Maximum net income 0, Minimum net income -151 184. The maximum price of CLDX shares is 396.15, the minimum price is 2.31.
.
CLDX valuation
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-3,96 | -7,11 | -25,84 | -16,22 | -6,33 | -2,57 | -3,87 | -0,42 | -0,66 | -5,25 | -7,56 |
P/B |
2,58 | 4,39 | 6,59 | 9,05 | 2,78 | 1,24 | 1,52 | 0,52 | 0,36 | 1,50 | 2,16 |
P/S |
19,14 | 37,51 | 512,51 | 534,00 | 146,99 | 48,63 | 28,24 | 6,73 | 9,38 | 42,28 | 60,94 |
E/P |
-25% | -14% | -4% | -6% | -16% | -39% | -26% | -235% | -152% | -19% | -13% |
P/FCF |
-4,90 | -8,39 | -29,31 | -18,51 | -7,76 | -2,85 | -3,54 | -0,84 | -0,71 | -7,48 | -10,77 |
.
CLDX profitability
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
ROE |
-65% | -62% | -26% | -56% | -44% | -48% | -39% | -122% | -54% | -29% | |
ROA |
-70% | -64% | -26% | -54% | -41% | -61% | -59% | -141% | -69% | -29% | |
ROIC |
-52% | -54% | -25% | -55% | -42% | -38% | -38% | -53% | -49% | -22% |